Navigation Links
OncoGenex Pharmaceuticals Names Michelle Burris Executive Vice President, Operations and Chief Financial Officer
Date:11/8/2010

, varied clinical pipeline, and growth prospects presents a compelling opportunity," said Ms. Burris.

Ms. Burris also sits on the board of directors of the Washington Biotechnology and BioMedical Association and the Executive Advisory Board of the Albers School of Business and Economics at Seattle University. She holds a Postgraduate Certificate in accounting and an MBA from Seattle University, a BS from George Mason University, and she has passed the CPA exam. About OncoGenex OncoGenex is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceuticals have entered a global collaboration and license agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen.  Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer. The companies plan to begin Phase 3 development of custirsen in first-line treatment of advanced, unresectable non-small cell lung cancer in 2011; OGX-427 is in Phase 2 clinical development; SN2310 has completed a Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development. More information is available at www.OncoGenex.com. OncoGenex's Forward Looking Statements This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning Ms. Burris' appointment and our anticipated product development activities. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. OncoGenex Reports Third Quarter Financial Results
2. OncoGenex Pharmaceuticals, Inc. Closes $50 Million Public Offering
3. OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering
4. OncoGenex Pharmaceuticals, Inc. Announces Proposed Public Offering
5. OncoGenex Pharmaceuticals to Present at the 9th Annual BIO Investor Forum
6. TEVA AND ONCOGENEX ANNOUNCE INITIATION OF SECOND PHASE 3 TRIAL OF CUSTIRSEN IN MEN WITH METASTATIC PROSTATE CANCER
7. OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
8. OncoGenex Reports Second Quarter Financial Results
9. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
10. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
11. OncoGenex Reports First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... this month, a report was created by Colorado ... Force on the performance of vehicles using an eco-friendly, ... fuel made from mustard seeds, offered great potential as ... friendly future. In fact, every branch of the U.S. ... foreign oil over the next few years. They will ...
(Date:8/28/2014)... August 28, 2014 Supplementing their ... a promotion for Eppendorf Safe Lock Centrifuge ... purchase the highest quality tubes at an affordable ... for customers doing chemical, medical, pharmaceutical, and life ... are not regularly able to afford Eppendorf products. ...
(Date:8/27/2014)... 27, 2014 Varian Medical Systems today ... current Salt Lake City manufacturing facility and allow for ... to ultimately create 1,000 new full time jobs in ... “Utah is home to hardworking people with immense engineering ... with Varian’s success in the manufacturing of our state-of-the-art ...
(Date:8/27/2014)... , Aug. 27, 2014 Rhythm, a biopharmaceutical ... genetic deficiencies that result in metabolic disorders, announced today ... S-1 with the U.S. Securities and Exchange Commission (SEC) ... of its common stock. The number of shares to ... have not yet been determined. Citigroup and ...
Breaking Biology Technology:Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 2Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 4Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 5Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 2Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 3Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 2Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 3Rhythm Files Registration Statement for Proposed Initial Public Offering 2
... , , , ... (Nasdaq: CALP ), a leading provider of tools ... introduced the IVIS Lumina XR in vivo imaging system, the ... system combines highly sensitive bioluminescence and fluorescence molecular optical imaging ...
... , , PHILADELPHIA, Sept. ... Professionals Society) conference in booth #607, Prolifiq announced software ... increasingly complex web of regulations governing sales communication. Prolifiq ... companies--is used to organize, send and track approved digital ...
... ... patients. Daniel Neal from Palm Springs, CA, gains the ability and confidence to put his ... ... improves walking for Parkinson,s disease patients. Daniel Neal from Palm Springs, CA, gains the ability ...
Cached Biology Technology:Caliper Life Sciences Launches IVIS(R) In Vivo Imaging System with X-Ray 2Caliper Life Sciences Launches IVIS(R) In Vivo Imaging System with X-Ray 3Prolifiq Announces Software for Life Sciences: Accelerates Sales, Embeds Adherence to Regulatory Compliance, Incorporates Good Promotional Practices 2Prolifiq Announces Software for Life Sciences: Accelerates Sales, Embeds Adherence to Regulatory Compliance, Incorporates Good Promotional Practices 3New Superman Glasses for Parkinson's Disease Improve Walking and Quality of Life 2
(Date:8/28/2014)... 2014A new method for measuring and imaging how quickly ... researchers better understand how drug abuse affects the brain, ... engineering, and lead to better treatment options for recovering ... of researchers from Stony Brook University in New York, ... published today in The Optical Society,s (OSA) open-access journal ...
(Date:8/28/2014)... kilometres of new roads will be built worldwide by ... last wildernesses, where they bring an influx of destructive ... ambitious study has created a ,global roadmap, for prioritising ... the competing demands of development and environmental protection. , ... estimates that natural importance of ecosystems and a ,road-benefits, ...
(Date:8/28/2014)... in homes could pose a significant health risk to people ... Journal of Allergy and Clinical Immunology . , By ... countries, the research has found that the presence of several ... sufferers, as well as increasing the likelihood of developing the ... at the University of Exeter Medical School and is the ...
Breaking Biology News(10 mins):This is your brain's blood vessels on drugs 2This is your brain's blood vessels on drugs 3Study shows where on the planet new roads should and should not go 2Study shows where on the planet new roads should and should not go 3Indoor mold poses health risk to asthma sufferers 2
... If you don,t know how a human cell is supposed ... the cell goes haywire -- as it does in cancer. ... has been awarded a $1.2 million grant to explore the ... and their connections to human disease. Tim Megraw, a ...
... WASHINGTONThe Wilson Center,s Synthetic Biology project recently ... One will support a Transatlantic Exploratory Workshop on ... and Policy, and the other will support research ... explore emerging issues in synthetic biology. The ...
... New species are not just discovered in exotic ... of new plants and animals. Academy scientists recently named ... group of fishes distantly related to sharks, from the ... new species, the Eastern Pacific black ghostshark ( Hydrolagus ...
Cached Biology News:Researcher awarded $1.2 million grant to study centrosomes and cilia 2New species of ghostshark from California and Baja California 2
... Acridinium NHS ester can ... and nucleic acids. The covalently ... produce chemiluminescence in the presence ... ester-labeled proteins can be used ...
... cytometry accessible to anyone in the lab. Novice ... to Guavas on-demand microcapillary flow cytometry systems ... surprisingly affordable, very compact, and nicely equipped with ... EasyCyte Mini has all of the functionality of ...
... Cell Lab Quantas unique combination of ... population resolution capabilities and accurate cell ... excitation wavelengths, including UV, allowing flexible ... multi-color applications typically only achievable with ...
... 250 g monoclonal antibody irreversibly crosslinked ... ~13 g of PDH complex from heart ... bovine heart mitochondria for control immunocapture. ,The ... isolation of PDH from small amounts of ...
Biology Products: